凉血疏肝方对寻常型银屑病患者血清神经肽Y影响的研究
|
摘要
目的：
观察中药凉血疏肝方的临床疗效,并测定寻常型银屑病患者经凉血疏肝方治疗前后血清神经肽Y水平,以及与正常人血清神经肽Y水平的对比,继而探讨中药凉血疏肝方对寻常型银屑病患者血清神经肽Y的影响,为分析凉血疏肝方的作用机制提供实验依据。
方法：
本研究采用随机、单盲、对照的临床研究方法,将75例合格入选病例随机分为治疗组和对照组,选取我院体检健康者29例。治疗组予凉血疏肝方,对照组予雷公藤多甙片,疗程一个月。在治疗前后分别对合格入选病例进行银屑病皮损面积和严重性指数(PASI)评分,用酶联免疫法测定两组治疗前后以及正常人血清神经肽Y的浓度。观察治疗后两组的临床疗效、治疗前后银屑病皮损面积和严重性指数(PASI)评分以及血清神经肽Y的变化,检测血液分析、肝肾功能等客观的实验室指标,并记录治疗过程中的不良反应。
结果：
1.治疗前两组性别、年龄、病程、PASI积分无显著性差异(P>0.05),具有可比性。2.治疗组总有效率为81.1%,对照组总有效率为84.2%,两组相比,经X2检验,无显著性差异(P>0.05)。3.治疗后两组PASI评分均较治疗前显著下降,治疗前后比较,经t检验,差异均有非常显著性意义(P<0.01)；两组治疗后疗效比较,经t检验,无显著性差异(P>0.05)。4.治疗前两组血清神经肽Y水平统计学无显著性差异(P>0.05),但是均显著高于正常人水平(P<0.01),经两种方法治疗后,治疗组血清神经肽Y水平有显著下降(P<0.01),与正常人相比统计学无显著性差异(P>0.05),对照组血清神经肽Y水平无明显下降(P>0.05)。5.安全性观察：两组均未出现明显的不良反应。
结论：
1.凉血疏肝方治疗银屑病疗效确切,可以起到和雷公藤多甙片相似的治疗效果。2.银屑病患者血清神经肽Y水平高于正常人。3.凉血疏肝方可以降低银屑病患者血清神经肽Y的浓度,而雷公藤多甙片不能。4.凉血疏肝方的作用机制可能是通过疏肝解郁,降低了情绪应激反应导致的神经肽Y的释放,干扰了皮肤局部的炎症及免疫反应而起到治疗作用。5.该方法安全、有效、副作用小,值得临床推广应用。
Object ive
Observation of clinical curative effect of TCM blood-cooling and soothing the liver and determination in patients with Psoriasis Vulgaris treated by blood-cooling and soothing the liver and serum levels of neuropeptide Y as well as the normal human serum levels of neuropeptide Y, than discussion the traditional Chinese medicine prescription on effect of the serum levels of neuropeptide Y in patients with Psoriasis Vulgaris, and provide experimental basis for the analysis of mechanism of blood-cooling and soothing the liver.
Methods
This study used a randomized, single-blind, placebo-controlled clinical study,75cases subjects were randomly divided into treatment and control groups, and select medical health29cases in our hospital. Treatment group to blood-cooling and soothing the liver, control group given TWP, course of treatment for a month. Respectively on the subjects before and after treatment for skin lesions of psoriasis area and severity index (PASI) score, and enzyme-linked immunoassay for determination of subjects before and after treatment, and neuropeptide Y in normal human serum concentration. Observation of clinical curative effect of two group before and after treatment, skin lesions of psoriasis area and severity index (PASI) score and the serum changes of neuropeptide Y, testing blood analysis, objective laboratory indices of liver and kidney function, and adverse reactions recorded in the treatment process.
Result
1.Comparing sex, age, course of disease and PASI scores before treatment, there were no significant difference between two groups.2. Treatment group total effective rate of81.1%,control group total effective rate of84.2%, compared to the two groups by X2tests, there were no significant difference (P>0.05).3. After treatment of the two groups marked reduction in PASI score than before treatment, compared before and after the treatment by t test, the differences are very significant implications (P<0.01);Comparison of therapeutic effect after the two groups by t tests, there were no significant difference (P>0.05).4. Two sets of neuropeptide Y concentration compared to normal before the treatment, the difference has a very significant meaning (P<0.01); Compared to the two sets of their neuropeptide Y concentration before and after treatment by t test, treatment of group therapy has a very significant meaning difference (P<0.01), Compared to the normal, there were no significant difference (P>0.05). Control group were no significant difference (P>0.05) compared with before treatment.5. Safety observation: two groups of all did not appear obvious adverse reactions.
Conclusion
1. Psoriasis treated by TCM blood-cooling and soothing the liver have a definite therapy effect, can play a similar treatment with tripterygium effect.2. The level of neuropeptide Y in serum of patients with psoriasis is higher than normal.3. TCM blood-cooling and soothing the liver can reduces the neuropeptide Y concentration in serum of patients with psoriasis, TWP cannot.4. The mechanism of TCM blood-cooling and soothing the liver may be through the liver qi stagnation, reducing the release of emotional stress reaction caused by neuropeptide Y of, interferes with the skin, local inflammation and immune responses play a therapeutic role.5. The method for safe, effective, small side-effects, and clinical application.
观察中药凉血疏肝方的临床疗效,并测定寻常型银屑病患者经凉血疏肝方治疗前后血清神经肽Y水平,以及与正常人血清神经肽Y水平的对比,继而探讨中药凉血疏肝方对寻常型银屑病患者血清神经肽Y的影响,为分析凉血疏肝方的作用机制提供实验依据。
方法：
本研究采用随机、单盲、对照的临床研究方法,将75例合格入选病例随机分为治疗组和对照组,选取我院体检健康者29例。治疗组予凉血疏肝方,对照组予雷公藤多甙片,疗程一个月。在治疗前后分别对合格入选病例进行银屑病皮损面积和严重性指数(PASI)评分,用酶联免疫法测定两组治疗前后以及正常人血清神经肽Y的浓度。观察治疗后两组的临床疗效、治疗前后银屑病皮损面积和严重性指数(PASI)评分以及血清神经肽Y的变化,检测血液分析、肝肾功能等客观的实验室指标,并记录治疗过程中的不良反应。
结果：
1.治疗前两组性别、年龄、病程、PASI积分无显著性差异(P>0.05),具有可比性。2.治疗组总有效率为81.1%,对照组总有效率为84.2%,两组相比,经X2检验,无显著性差异(P>0.05)。3.治疗后两组PASI评分均较治疗前显著下降,治疗前后比较,经t检验,差异均有非常显著性意义(P<0.01)；两组治疗后疗效比较,经t检验,无显著性差异(P>0.05)。4.治疗前两组血清神经肽Y水平统计学无显著性差异(P>0.05),但是均显著高于正常人水平(P<0.01),经两种方法治疗后,治疗组血清神经肽Y水平有显著下降(P<0.01),与正常人相比统计学无显著性差异(P>0.05),对照组血清神经肽Y水平无明显下降(P>0.05)。5.安全性观察：两组均未出现明显的不良反应。
结论：
1.凉血疏肝方治疗银屑病疗效确切,可以起到和雷公藤多甙片相似的治疗效果。2.银屑病患者血清神经肽Y水平高于正常人。3.凉血疏肝方可以降低银屑病患者血清神经肽Y的浓度,而雷公藤多甙片不能。4.凉血疏肝方的作用机制可能是通过疏肝解郁,降低了情绪应激反应导致的神经肽Y的释放,干扰了皮肤局部的炎症及免疫反应而起到治疗作用。5.该方法安全、有效、副作用小,值得临床推广应用。
Object ive
Observation of clinical curative effect of TCM blood-cooling and soothing the liver and determination in patients with Psoriasis Vulgaris treated by blood-cooling and soothing the liver and serum levels of neuropeptide Y as well as the normal human serum levels of neuropeptide Y, than discussion the traditional Chinese medicine prescription on effect of the serum levels of neuropeptide Y in patients with Psoriasis Vulgaris, and provide experimental basis for the analysis of mechanism of blood-cooling and soothing the liver.
Methods
This study used a randomized, single-blind, placebo-controlled clinical study,75cases subjects were randomly divided into treatment and control groups, and select medical health29cases in our hospital. Treatment group to blood-cooling and soothing the liver, control group given TWP, course of treatment for a month. Respectively on the subjects before and after treatment for skin lesions of psoriasis area and severity index (PASI) score, and enzyme-linked immunoassay for determination of subjects before and after treatment, and neuropeptide Y in normal human serum concentration. Observation of clinical curative effect of two group before and after treatment, skin lesions of psoriasis area and severity index (PASI) score and the serum changes of neuropeptide Y, testing blood analysis, objective laboratory indices of liver and kidney function, and adverse reactions recorded in the treatment process.
Result
1.Comparing sex, age, course of disease and PASI scores before treatment, there were no significant difference between two groups.2. Treatment group total effective rate of81.1%,control group total effective rate of84.2%, compared to the two groups by X2tests, there were no significant difference (P>0.05).3. After treatment of the two groups marked reduction in PASI score than before treatment, compared before and after the treatment by t test, the differences are very significant implications (P<0.01);Comparison of therapeutic effect after the two groups by t tests, there were no significant difference (P>0.05).4. Two sets of neuropeptide Y concentration compared to normal before the treatment, the difference has a very significant meaning (P<0.01); Compared to the two sets of their neuropeptide Y concentration before and after treatment by t test, treatment of group therapy has a very significant meaning difference (P<0.01), Compared to the normal, there were no significant difference (P>0.05). Control group were no significant difference (P>0.05) compared with before treatment.5. Safety observation: two groups of all did not appear obvious adverse reactions.
Conclusion
1. Psoriasis treated by TCM blood-cooling and soothing the liver have a definite therapy effect, can play a similar treatment with tripterygium effect.2. The level of neuropeptide Y in serum of patients with psoriasis is higher than normal.3. TCM blood-cooling and soothing the liver can reduces the neuropeptide Y concentration in serum of patients with psoriasis, TWP cannot.4. The mechanism of TCM blood-cooling and soothing the liver may be through the liver qi stagnation, reducing the release of emotional stress reaction caused by neuropeptide Y of, interferes with the skin, local inflammation and immune responses play a therapeutic role.5. The method for safe, effective, small side-effects, and clinical application.
引文
[1]中医医院.赵炳南临床经验集[M].北京：人民卫生出版社,1979：211.
[2]秦万章.皮肤病研究[M].上海：上海科学技术出版社,1990：32.
[3]顾伯华.中医外科临床手册[M].上海：上海科学技术出版社,1986：234.
[4]徐宜厚.皮肤病中医诊疗简编[M].武汉：湖北人民出版社,1980.
[5]钟金宝,殷新.榻国维教授治疗银屑病经验介绍[J].新中医,2004,36(9)：11-12.
[6]黄静,李薇.钟以泽辨治银屑病经验[J].四川中医,2004,22(8)：4.
[7]韩永群,袁广琪,祝连庆,等.从阴虚瘀热论治银屑病与血液流变学的相关性[J].山西临床医药,2001,10(4)：264..265.
[8]刘爱民.运用温法.散法治疗寻常型银屑病体会[J].中医杂志.2009.50(9)：792-793.
[9]金立,姜燕生.银屑病的发病特点与中医学肝的生理功能的相关性分析[J].实用皮肤病学杂志,2009年9月第2卷第3期：163-165.
[10]张晓杰,耿立东,寻常型银屑病病因病机探讨[J].山东中医杂志,2001,20(10)586-587.
[11]吴敦序.中医基础理论[M].上海：上海科学技术出版社,199811301.
[12]金·刘元素.素问玄机原病式[M].南京：江苏科学技术出版社,19851271.
[13]中医科学院广安门医院.朱仁康临床经验集.北京：人民卫生出版社,1979,10：153-158.
[14]周鸣岐.辨证分型治疗银屑病302例.中医杂志,1989,30(5)：42-43.
[15]张志礼.张志礼皮肤病临床经验辑要[M].北京：中国医药科技出版社,2002.
[16]马绍尧,李咏梅.辨证治疗寻常型银屑病312例.湖南中医药导报,1999,5(7)：21.
[17]练蔼云.范瑞强教授治疗银屑病经验漫谈[J].现代中西医结合杂志,2004,13(5)582.
[18]李庄原.银屑病的中医辨证治疗.临床医药实践杂志,2008,17(8)：693-694.
[19]李燕燕,贾海骥.中医辨证分型治疗银屑病[J].中国中医基础医学杂,2009,15(1)：66.
[20]杨洪蒲,张云宵,王占杰.潜阳散结法治疗斑块状银屑病[J].天津中医,2000,17(4)：封4.
[21]何玲,吴淞.牛黄冲剂治疗寻常型银屑病59例临床观察[J].中医杂志,2002,43(2)：123-124
[22]徐荣华.荆防地蚤汤治疗小儿银屑病20例疗效观察[J].中国自然医学杂志,2003,5(3)：171.
[23]陈恩军.桂枝汤加味治疗银屑病78例[J].陕西中医,2005,26(5)：446.
[24]王雨甄.刘瑛琦治疗寻常型银屑病经验[J].中国中医药信息杂志,2008,15(5)：90-91.
[25]李寿甫,杨占魁.脏腑辩证分型治疗银屑病1000例[J].陕西中医,1998,19(2)：60-61.
[26]苗丹民.影响银屑病患者的心理状态因素的逐步回归分析[J].中国皮肤性病学杂志,1994,8(2)：68.
[27]韩晓冰,姚尚萍.疏肝理气法治疗银屑病80例[[J].河南中医,2007,27(3)：53.
[28]刘卫兵,王梦柏.从肝论治银屑病60例[J].皮肤与性病,1996,18(1)：89-90.
[29]叶建州.加味逍遥散配合心理咨询治疗成年女性银屑病34例疗效观察[J].1997,18(5)：12-13.
[30]王锁杏.逍遥丸配合常规疗法治疗顽固性寻常性银屑病26例[J].陕西中医,2001,22(12)：733-734.
[31]解品启,李洁.克银方合逍遥丸疗寻常型银屑病40例临床观察[J].山西中医,2003,19(3)：18-19.
[32]吴文媛,金岚,秦万章.雷公藤糖浆治疗190例银屑病临床疗效观察[J].中国皮肤性病杂志,1991,5(1)：27.
[33]张福仁,田仁明,马世尧等.雷公藤治疗进行期寻常型银屑病的随机双盲研究[J].临床皮肤科杂志,1999,28(1)：32-33.
[34]王禾,杨慧敏,王萍,等.关节病性银屑病34例临床分析与中西医结合治疗[J].中国中西医结合皮肤性病学杂志,2005,4(4)：217-218.
[35]复方青黛胶囊治疗银屑病协作组.复方青黛胶囊治疗银屑病疗效观察[J].中华皮肤科杂志,2000.33(2)：139.
[36]历志,刘丽红,张淑英.银屑病的中西医治疗现状[J].中医药信息,2005,22(5)：27.
[37]段有超,朱春才.苦参汤外洗治疗寻常型银屑病58例观察[J].中医药信息,2004,21(5)：27.
[38]林胤谷,吴宜鸿,杨荣季,等.复方青黛油膏治疗银屑病的临床疗效评估[J].成都中医药大学学报,2006,29(2)：13-17.
[39]王旭龙,叶平,段军安.复方牛蒡子油外治寻常型银屑病效果观察[J].临床检验知识,2000,7(4)：47.
[40]王瑛,白长川,高文婷等.土槐煎剂治疗寻常型银屑病实验研究[J].中国麻风皮肤病杂,志,2006,22(4)：297-298.
[41]白英华,田静,金春林.凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响[J].中国中西医结合皮肤性病学杂志,2006,5(3)：144.
[42]姜相德,李进等,王素文.银屑灵涂膜剂治疗银屑病的实验研究[J].天津医药,2002,19(5)：39-41.
[43]杨志波,向亚萍,欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子a水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[44]钱方,杨志波,欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报,2004,10(12)：54-55,59.
[45]范斌,李斌,章云,等.凉血和活血中药对银屑病患者进行期和静止期血浆中P物质、β-内啡肽分泌的影响[J].上海中医药杂志,2006,40(10)：34-35.
[46]齐凤琴姜淑凤富学东.增液消银汤对银屑病患者神经肽水平的影响[J].中国煤炭工业医学杂志,2007,10(9)：1071.
[47]刘小银,曹娜,刘娜.凉血解毒饮治疗血热型银屑病疗效观察及对人血清P物质的影响[J].中医药导报,2011,17(8)：31-33.
[48]干禾,干萍,孙丽蕴等.凉血.活血.胶囊治疗银屑病血热证的临床观察及外周血巴细胞亚 群检测[J].中国皮肤性病学杂志,2004,18(3)：176-177.
[49]包佐义.复方丹参配合静脉封闭治疗银屑病32例及甲襞微循环观察[J].皮肤病与性病,1997,19(1)：11.
[50]Lomholt G. PREVALENCE OF SKIN DISEASES IN A POPULA-TION;A CENSUS STUDY FROM THE FAROE ISLANDS [J]. DanMed Bull,1964,11:1-7.
[51]bowcock AM, Barker JN. Genetics of psoriasis:the potential impact on new therapies,J Am Acad Dermatol 2003; 49(1):51-56.
[52]郑敏.银屑病发病机制研究中若干问题的思考[J].中华皮肤科杂志,2006,39(13)：121-123.
[53]kruegerJG. The immunologic basis for the treatment of Psoriasis with New biologic agents[J]. Jam Demratol.2002.46(1):1-23
[54]朱可建,商惠英,劳力民等.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达[J].中华皮肤科杂志,2003,36(3)：142-144.
[55]董峰,李新华,张开明,等.银屑病患者造血细胞定向分化的CD4+CD25+ 调节性T细胞活性研究[J].临床皮肤科杂志,2008,37(4)：207-209.
[56]Sug iyam a H, GyulaiR, Toich iE, et a.1 Dysfunctional blood and target tissue CD4+ CD25 high regulatory T cells in psoriasis mechanism underlying unrestrained pathogen ic effector T cellproliferation[J]. J Imm un o,l 2005,174(1):164-173.
[57]Bagel J, Garland WT, Breneman D, et al. Administrat ion of DAB389IL22 to pat ients with reculeit rant psoriasis:a double blind, phase O mult icent er trial [J]. J Am Acad Dermatol,1998,38(6):938-944.
[58]王支琼,李家文.银屑病患者白介素-18及其受体的辅助性非结合链和白介素-18结合蛋白mRNA的表达[J].中华皮肤科杂志,2003,36(7)：403.
[59]FARBER E M,NICK EOLOFF B J,RECHT B, ea tl. Stress, symmetry, and psoriasis: possible role of neuropeptides[J]. J Am Acad Dermatol,1986,14:305
[60]杨雪琴,李铀,李炜等.银屑病患者的心率变异性研究[J].中华皮肤科杂志,1997,30(2)：115-117.
[61]李春阳,王英杰,王克玉等.银屑病患者的心理因素及外周血.单胺类物质的改变[J].中华皮肤科杂志,2003,36(3)：145-147.
[62]罗南萍,刘翠杰,杨道理.NPY与NT在银屑病患者中的检测及临床意义研究[J].中国皮肤性病学杂,1999,13(5)：267-268.
[63]Harvima IT, Viinamaki H, Naukkarinen A et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom 1993; 60:168-76.
[64]Chu DQ, Choy M, Foster P et al. A comparative study of the abil ity of calcitonin gene-related peptide and adrenomedullin (13-52) to modulate microvascular but not thermal hyperalgesia responses. BrJ Pharmacol 2000; 130:1589-96.
[65]姚聪君,王俊民,谭升顺.银屑病患者皮损内及血中神经肽(SP、SS)的研究,中国皮肤 性病学杂志,1998,12(1)：5-6.
[66]Fantini F et al. J Invest Dermatol,1995,105:854-855.
[67]Tokura, et al. Arch Dermatol Res,1999,291(7-8):38.
[68]Yamaoto, et al. Eur J Dermatol,1999,9 (1):17.
[69]Weissenborn, et al. J Invest Dermatol,1999,113(1):122
[70]Weitzul, et al. Semin Cutan Med Surg,1997,16(3):213.
[71]Squiquera L, et al. Clin Exp Dermatol,1994,19(4):289.
[72]FARBER E M, BRIGHT R D, NALL ML. Psoriasis. Aquestionnaire survey of 2144 patients[J]. Arch Dermatol,1968,98(3):248-259.
[73]Harvima RJ, iinamaki H, harvima IT, ea tl. Association of psychic stress with clinical severity and symptoms of psoriatic patients[J]. ActaDerm Venereol,1996, 76:467-471.
[74]巩杰,楼有益,向贤华等.社会心理因素与银屑病关系的初步探讨[J].中国皮肤性病学杂志,1991,5(3)：139-141.
[75]李梓霞,路云环.银屑患者社会心理因素调查及心理干预[J].护理研究,2006,20(10)：2649-2651.
[76]Yasuda H, Kobayashi H, Ohkawara A. A survey of the social and psychological effects of psoriasis. Nippin Hifuka Gakkaai Zasshi,1990,100:1167.
[77]刘涛峰,张学军,杨森等.银屑病诱发因素的对照研究.中华皮肤科杂志,2000：33(5)：351-352.
[78]张雪.复方甘草酸苷寻常型银屑病疗效观察[J].中国医院用药评价与分析,2007,7(4)：299-300.
[79]任杰,王国安,杜秋燕.甲氨蝶呤联合小剂量叶酸治疗中重度银屑病疗效观察[J].中国皮肤性病学杂志,2007,21(12)：761.
[80]常梓香,温晨东.阿维A对寻常型银屑病患者血清肿瘤坏死因子-a、C反应蛋白水平的影响.山西医药杂志,2009,38：1010-1011.
[81]朱学骏,顾有守,沈丽玉等.实用皮肤病性病治疗学[M].北京：北京医科大学、中国协和医科大学联合出版社,1996.59-60.
[82]ANTONI C, KAVANAUGH A, KIRKHAM B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis:results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J] Arthritis Rheum,2005,52 (4):1227-1236.
[83]李娟,蒋春梅,任洁.抗TNF-α单克隆抗体治疗银屑病及银屑病关节炎临床评价[J]新医学2011,42(6)：363-366.
[84]Pershadsingh HA, Sproul JA, Benjamin E。 et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134:1304-1305.
[85]Ellis CN, Varani J, Fisher GJ, et al. Troglitazone implroves psoriasis and normalizes models of proliferator skin disease,ligands for peroxisome p roliferator--activated receptor-gamma inhibit keratinoeyte proliferation. Arch Dermatol 2000; 136:609-616.
[86]Mittal R,Malhotra S,Pandhi P, et al. Efficacy and safety of combination acitretin and Pioglitazorie therapy in patients with moderate to severe chronic plaque—type psoriasis:a randomized. double—blind, placebo—controlled clinical trial. Arch Dermatol 2009; 145:387—393.
[87]张建玲.寻常型银屑病的治疗及研究进展[J].中国临床新医学2009,2(10)：1117
[88]陈爱明.卡泊三醇联合卤米松治疗银屑病临床分析[J].当代医学,2011,17(22)：143-144.
[89]黄世杰摘.新药研究与开发[J].国际药学研究杂志,2011,38(2)：114.
[90]Reit amo S, Spuls P, Sassolas B, et al. A double- blind study in patient s w ith severe psoriasis t o assess the clinical act ivit y an d saf et y of rapamycin (sirolimus) alone or in associat ion w ith a reduced dose of cyclosporin, Br J Dermat ol,1999,141:978-979 (Abstr)
[91]Krofl EB, Erceg A, Maimets K, et al. Tacrolimus ointment for the treatment of severe facinl plaque psoriasis[J]. J Eur Acad Dermatol Venereol.2005,19(2):249-251.
[92]Gara S, Boussen H, Ghanem A, et al. Use of common seric tumor markers in patients with solid cancers [J]. Tunis Med,2008,86 (6):579-583.
[93]NaiK VK, Joshi UM, Sheth AR. Long-term effects of vasectomy on prostatic function in men [J]. J Reprod Fertil,1980,58 (2):289-293.
[94]张忠华,赵梓纲,J‘香玉等.窄谱中波紫外线联合他扎罗汀凝胶治疗寻常型银屑病疗效观察[J].军医进修学院学报,2011,32(2)：153-154,162.
[95]S ticherl ingM, Saut ierW, Sch roder JM, et a.l Interleuk in-8 p lays its role at local levelin p sorias is vu lgaris. A cta Derm Ven ereo,l 1999;79:4-8.
[96]史月君,唐春蕾.中药浴与光疗联合治疗银屑病的临床观察[J].中国麻风皮肤病杂志,2006,22(9)：792.
[97]Kirby B, RichardsHL, McElhon e K, et al. Psychological distress affects the ef ficacy of PUVA in patient s w ith psoriasis. Br J Dermat ol,2000,143 (Suppl 57):15-24
[98]杨雪琴,张高明,张力军.生物反馈治疗银屑病的探讨.中华皮肤科志,1993,26：119-120.
[99]路云环,李桂霞,范慧英.心理治疗对银屑病患者的影响[J].中国麻风皮肤病杂志,2007,23(11)：969.
[100]陈春华,李敏,李涛.心理行为干预对银屑病患者的影响[J].临床护理,2011,9(4)：154.
[101]孔素云,王东.寻常型银屑病89例的心理测查及心理治疗[J].中华现代临床医学杂志,2005,3(16)：1663-1664.
[102]刘巧,吴伟伟,王爱民.系统性心理行为干预对银屑病患者影响的研究[J].中国中西医结合皮肤性病学杂志,2011,10(1)：56-58.
[103]康小平,吴志洪.放松和想象训练与药物联合治疗银屑病疗效分析[J].皮肤性病诊疗学杂志,2011,18(5)：327-328.
[104]王禾,孙丽蕴,邓丙戌等.靛玉红紫草素对角质形成细胞株凋亡的影响[J].中国麻风皮肤病杂志,2003,18(6)：325-327.
[105]刘梅青.不同剂量紫草醇提取物对表皮细胞过度增殖的实验研究[J].临床医药实践杂志2003;12(7)：485.
[106]Arbiser JL, KlauberN, Rohan R, et al. Curcumin is an in vivo in-hibitor of angio2genesis[J]. MolMed,1998,4(6):376.
[107]吴京海,杨思源,金岚等.丹参素对银屑病患者外周血单个核细胞粘附分子表达的影响[J].上海医科大学学报,1998,25(1)：47.
[108]赵喜荣,李冠勇,季军捷等.复方丹参液对银屑病患者血液MDA、SOD及红细胞四项指数的影响[J].临床皮肤科杂志,1995,(4)：25.
[109]王英杰,范慧英,路云环.复方甘草酸苷对银屑病患者T细胞免疫功能的影响[J]中国麻风皮肤病杂志,2007,23(6)：533.
[110]刘晓明,孙秀坤,齐欣,等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素-的影响[J].中华皮肤科杂志,2001,34(4)：282-283.
[111]王学军,陶以成,刘长发.丹槐银屑浓缩丸对小鼠银屑病模型的病理实验研究[J].中国中医急症,2010,19(1)：104-105.
[112]张云璧,瞿幸,牛福玲.常用治疗银屑病的中药对肿瘤坏死因子-α刺激后角质形成细胞生长及分泌白介素-8的影响[J].中国中西医结合皮肤性病学杂志,2006,5(1)：19.
[113]杜锡贤,张春红.张春敏等.清热凉血法治疗进行期寻常型银屑病的临床和实验研究[J].中国麻风皮肤痛杂志.2005,21(11)：896
[114]许能,吴胜利,马绍尧.凉血解毒中药治疗银屑病的实验研究[J].上海中医药大学学报,2004,18(2)：61.
[115]Picardi A,Pasouini P. Toward a biopsychosocial approach to skin diseases [J].Adv Psychosom Med,2007,5 (2):137-144.
[116]M isery L. Sk in, immunity and n ervou s system [J]. B r J Derm ato,l 1997, 137(6):843-850.
[117]谢启文主编.现代神经内分泌学[M].上海：上海医科大学出版社.1999年：69-70
[118]杨道理,罗南萍.银屑病患者NPY、NT、TNF、HA及LN检测的临床意义[J].放射免疫学杂志,1998,11(6)：348-349.
[2]秦万章.皮肤病研究[M].上海：上海科学技术出版社,1990：32.
[3]顾伯华.中医外科临床手册[M].上海：上海科学技术出版社,1986：234.
[4]徐宜厚.皮肤病中医诊疗简编[M].武汉：湖北人民出版社,1980.
[5]钟金宝,殷新.榻国维教授治疗银屑病经验介绍[J].新中医,2004,36(9)：11-12.
[6]黄静,李薇.钟以泽辨治银屑病经验[J].四川中医,2004,22(8)：4.
[7]韩永群,袁广琪,祝连庆,等.从阴虚瘀热论治银屑病与血液流变学的相关性[J].山西临床医药,2001,10(4)：264..265.
[8]刘爱民.运用温法.散法治疗寻常型银屑病体会[J].中医杂志.2009.50(9)：792-793.
[9]金立,姜燕生.银屑病的发病特点与中医学肝的生理功能的相关性分析[J].实用皮肤病学杂志,2009年9月第2卷第3期：163-165.
[10]张晓杰,耿立东,寻常型银屑病病因病机探讨[J].山东中医杂志,2001,20(10)586-587.
[11]吴敦序.中医基础理论[M].上海：上海科学技术出版社,199811301.
[12]金·刘元素.素问玄机原病式[M].南京：江苏科学技术出版社,19851271.
[13]中医科学院广安门医院.朱仁康临床经验集.北京：人民卫生出版社,1979,10：153-158.
[14]周鸣岐.辨证分型治疗银屑病302例.中医杂志,1989,30(5)：42-43.
[15]张志礼.张志礼皮肤病临床经验辑要[M].北京：中国医药科技出版社,2002.
[16]马绍尧,李咏梅.辨证治疗寻常型银屑病312例.湖南中医药导报,1999,5(7)：21.
[17]练蔼云.范瑞强教授治疗银屑病经验漫谈[J].现代中西医结合杂志,2004,13(5)582.
[18]李庄原.银屑病的中医辨证治疗.临床医药实践杂志,2008,17(8)：693-694.
[19]李燕燕,贾海骥.中医辨证分型治疗银屑病[J].中国中医基础医学杂,2009,15(1)：66.
[20]杨洪蒲,张云宵,王占杰.潜阳散结法治疗斑块状银屑病[J].天津中医,2000,17(4)：封4.
[21]何玲,吴淞.牛黄冲剂治疗寻常型银屑病59例临床观察[J].中医杂志,2002,43(2)：123-124
[22]徐荣华.荆防地蚤汤治疗小儿银屑病20例疗效观察[J].中国自然医学杂志,2003,5(3)：171.
[23]陈恩军.桂枝汤加味治疗银屑病78例[J].陕西中医,2005,26(5)：446.
[24]王雨甄.刘瑛琦治疗寻常型银屑病经验[J].中国中医药信息杂志,2008,15(5)：90-91.
[25]李寿甫,杨占魁.脏腑辩证分型治疗银屑病1000例[J].陕西中医,1998,19(2)：60-61.
[26]苗丹民.影响银屑病患者的心理状态因素的逐步回归分析[J].中国皮肤性病学杂志,1994,8(2)：68.
[27]韩晓冰,姚尚萍.疏肝理气法治疗银屑病80例[[J].河南中医,2007,27(3)：53.
[28]刘卫兵,王梦柏.从肝论治银屑病60例[J].皮肤与性病,1996,18(1)：89-90.
[29]叶建州.加味逍遥散配合心理咨询治疗成年女性银屑病34例疗效观察[J].1997,18(5)：12-13.
[30]王锁杏.逍遥丸配合常规疗法治疗顽固性寻常性银屑病26例[J].陕西中医,2001,22(12)：733-734.
[31]解品启,李洁.克银方合逍遥丸疗寻常型银屑病40例临床观察[J].山西中医,2003,19(3)：18-19.
[32]吴文媛,金岚,秦万章.雷公藤糖浆治疗190例银屑病临床疗效观察[J].中国皮肤性病杂志,1991,5(1)：27.
[33]张福仁,田仁明,马世尧等.雷公藤治疗进行期寻常型银屑病的随机双盲研究[J].临床皮肤科杂志,1999,28(1)：32-33.
[34]王禾,杨慧敏,王萍,等.关节病性银屑病34例临床分析与中西医结合治疗[J].中国中西医结合皮肤性病学杂志,2005,4(4)：217-218.
[35]复方青黛胶囊治疗银屑病协作组.复方青黛胶囊治疗银屑病疗效观察[J].中华皮肤科杂志,2000.33(2)：139.
[36]历志,刘丽红,张淑英.银屑病的中西医治疗现状[J].中医药信息,2005,22(5)：27.
[37]段有超,朱春才.苦参汤外洗治疗寻常型银屑病58例观察[J].中医药信息,2004,21(5)：27.
[38]林胤谷,吴宜鸿,杨荣季,等.复方青黛油膏治疗银屑病的临床疗效评估[J].成都中医药大学学报,2006,29(2)：13-17.
[39]王旭龙,叶平,段军安.复方牛蒡子油外治寻常型银屑病效果观察[J].临床检验知识,2000,7(4)：47.
[40]王瑛,白长川,高文婷等.土槐煎剂治疗寻常型银屑病实验研究[J].中国麻风皮肤病杂,志,2006,22(4)：297-298.
[41]白英华,田静,金春林.凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响[J].中国中西医结合皮肤性病学杂志,2006,5(3)：144.
[42]姜相德,李进等,王素文.银屑灵涂膜剂治疗银屑病的实验研究[J].天津医药,2002,19(5)：39-41.
[43]杨志波,向亚萍,欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子a水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[44]钱方,杨志波,欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报,2004,10(12)：54-55,59.
[45]范斌,李斌,章云,等.凉血和活血中药对银屑病患者进行期和静止期血浆中P物质、β-内啡肽分泌的影响[J].上海中医药杂志,2006,40(10)：34-35.
[46]齐凤琴姜淑凤富学东.增液消银汤对银屑病患者神经肽水平的影响[J].中国煤炭工业医学杂志,2007,10(9)：1071.
[47]刘小银,曹娜,刘娜.凉血解毒饮治疗血热型银屑病疗效观察及对人血清P物质的影响[J].中医药导报,2011,17(8)：31-33.
[48]干禾,干萍,孙丽蕴等.凉血.活血.胶囊治疗银屑病血热证的临床观察及外周血巴细胞亚 群检测[J].中国皮肤性病学杂志,2004,18(3)：176-177.
[49]包佐义.复方丹参配合静脉封闭治疗银屑病32例及甲襞微循环观察[J].皮肤病与性病,1997,19(1)：11.
[50]Lomholt G. PREVALENCE OF SKIN DISEASES IN A POPULA-TION;A CENSUS STUDY FROM THE FAROE ISLANDS [J]. DanMed Bull,1964,11:1-7.
[51]bowcock AM, Barker JN. Genetics of psoriasis:the potential impact on new therapies,J Am Acad Dermatol 2003; 49(1):51-56.
[52]郑敏.银屑病发病机制研究中若干问题的思考[J].中华皮肤科杂志,2006,39(13)：121-123.
[53]kruegerJG. The immunologic basis for the treatment of Psoriasis with New biologic agents[J]. Jam Demratol.2002.46(1):1-23
[54]朱可建,商惠英,劳力民等.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达[J].中华皮肤科杂志,2003,36(3)：142-144.
[55]董峰,李新华,张开明,等.银屑病患者造血细胞定向分化的CD4+CD25+ 调节性T细胞活性研究[J].临床皮肤科杂志,2008,37(4)：207-209.
[56]Sug iyam a H, GyulaiR, Toich iE, et a.1 Dysfunctional blood and target tissue CD4+ CD25 high regulatory T cells in psoriasis mechanism underlying unrestrained pathogen ic effector T cellproliferation[J]. J Imm un o,l 2005,174(1):164-173.
[57]Bagel J, Garland WT, Breneman D, et al. Administrat ion of DAB389IL22 to pat ients with reculeit rant psoriasis:a double blind, phase O mult icent er trial [J]. J Am Acad Dermatol,1998,38(6):938-944.
[58]王支琼,李家文.银屑病患者白介素-18及其受体的辅助性非结合链和白介素-18结合蛋白mRNA的表达[J].中华皮肤科杂志,2003,36(7)：403.
[59]FARBER E M,NICK EOLOFF B J,RECHT B, ea tl. Stress, symmetry, and psoriasis: possible role of neuropeptides[J]. J Am Acad Dermatol,1986,14:305
[60]杨雪琴,李铀,李炜等.银屑病患者的心率变异性研究[J].中华皮肤科杂志,1997,30(2)：115-117.
[61]李春阳,王英杰,王克玉等.银屑病患者的心理因素及外周血.单胺类物质的改变[J].中华皮肤科杂志,2003,36(3)：145-147.
[62]罗南萍,刘翠杰,杨道理.NPY与NT在银屑病患者中的检测及临床意义研究[J].中国皮肤性病学杂,1999,13(5)：267-268.
[63]Harvima IT, Viinamaki H, Naukkarinen A et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom 1993; 60:168-76.
[64]Chu DQ, Choy M, Foster P et al. A comparative study of the abil ity of calcitonin gene-related peptide and adrenomedullin (13-52) to modulate microvascular but not thermal hyperalgesia responses. BrJ Pharmacol 2000; 130:1589-96.
[65]姚聪君,王俊民,谭升顺.银屑病患者皮损内及血中神经肽(SP、SS)的研究,中国皮肤 性病学杂志,1998,12(1)：5-6.
[66]Fantini F et al. J Invest Dermatol,1995,105:854-855.
[67]Tokura, et al. Arch Dermatol Res,1999,291(7-8):38.
[68]Yamaoto, et al. Eur J Dermatol,1999,9 (1):17.
[69]Weissenborn, et al. J Invest Dermatol,1999,113(1):122
[70]Weitzul, et al. Semin Cutan Med Surg,1997,16(3):213.
[71]Squiquera L, et al. Clin Exp Dermatol,1994,19(4):289.
[72]FARBER E M, BRIGHT R D, NALL ML. Psoriasis. Aquestionnaire survey of 2144 patients[J]. Arch Dermatol,1968,98(3):248-259.
[73]Harvima RJ, iinamaki H, harvima IT, ea tl. Association of psychic stress with clinical severity and symptoms of psoriatic patients[J]. ActaDerm Venereol,1996, 76:467-471.
[74]巩杰,楼有益,向贤华等.社会心理因素与银屑病关系的初步探讨[J].中国皮肤性病学杂志,1991,5(3)：139-141.
[75]李梓霞,路云环.银屑患者社会心理因素调查及心理干预[J].护理研究,2006,20(10)：2649-2651.
[76]Yasuda H, Kobayashi H, Ohkawara A. A survey of the social and psychological effects of psoriasis. Nippin Hifuka Gakkaai Zasshi,1990,100:1167.
[77]刘涛峰,张学军,杨森等.银屑病诱发因素的对照研究.中华皮肤科杂志,2000：33(5)：351-352.
[78]张雪.复方甘草酸苷寻常型银屑病疗效观察[J].中国医院用药评价与分析,2007,7(4)：299-300.
[79]任杰,王国安,杜秋燕.甲氨蝶呤联合小剂量叶酸治疗中重度银屑病疗效观察[J].中国皮肤性病学杂志,2007,21(12)：761.
[80]常梓香,温晨东.阿维A对寻常型银屑病患者血清肿瘤坏死因子-a、C反应蛋白水平的影响.山西医药杂志,2009,38：1010-1011.
[81]朱学骏,顾有守,沈丽玉等.实用皮肤病性病治疗学[M].北京：北京医科大学、中国协和医科大学联合出版社,1996.59-60.
[82]ANTONI C, KAVANAUGH A, KIRKHAM B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis:results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J] Arthritis Rheum,2005,52 (4):1227-1236.
[83]李娟,蒋春梅,任洁.抗TNF-α单克隆抗体治疗银屑病及银屑病关节炎临床评价[J]新医学2011,42(6)：363-366.
[84]Pershadsingh HA, Sproul JA, Benjamin E。 et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134:1304-1305.
[85]Ellis CN, Varani J, Fisher GJ, et al. Troglitazone implroves psoriasis and normalizes models of proliferator skin disease,ligands for peroxisome p roliferator--activated receptor-gamma inhibit keratinoeyte proliferation. Arch Dermatol 2000; 136:609-616.
[86]Mittal R,Malhotra S,Pandhi P, et al. Efficacy and safety of combination acitretin and Pioglitazorie therapy in patients with moderate to severe chronic plaque—type psoriasis:a randomized. double—blind, placebo—controlled clinical trial. Arch Dermatol 2009; 145:387—393.
[87]张建玲.寻常型银屑病的治疗及研究进展[J].中国临床新医学2009,2(10)：1117
[88]陈爱明.卡泊三醇联合卤米松治疗银屑病临床分析[J].当代医学,2011,17(22)：143-144.
[89]黄世杰摘.新药研究与开发[J].国际药学研究杂志,2011,38(2)：114.
[90]Reit amo S, Spuls P, Sassolas B, et al. A double- blind study in patient s w ith severe psoriasis t o assess the clinical act ivit y an d saf et y of rapamycin (sirolimus) alone or in associat ion w ith a reduced dose of cyclosporin, Br J Dermat ol,1999,141:978-979 (Abstr)
[91]Krofl EB, Erceg A, Maimets K, et al. Tacrolimus ointment for the treatment of severe facinl plaque psoriasis[J]. J Eur Acad Dermatol Venereol.2005,19(2):249-251.
[92]Gara S, Boussen H, Ghanem A, et al. Use of common seric tumor markers in patients with solid cancers [J]. Tunis Med,2008,86 (6):579-583.
[93]NaiK VK, Joshi UM, Sheth AR. Long-term effects of vasectomy on prostatic function in men [J]. J Reprod Fertil,1980,58 (2):289-293.
[94]张忠华,赵梓纲,J‘香玉等.窄谱中波紫外线联合他扎罗汀凝胶治疗寻常型银屑病疗效观察[J].军医进修学院学报,2011,32(2)：153-154,162.
[95]S ticherl ingM, Saut ierW, Sch roder JM, et a.l Interleuk in-8 p lays its role at local levelin p sorias is vu lgaris. A cta Derm Ven ereo,l 1999;79:4-8.
[96]史月君,唐春蕾.中药浴与光疗联合治疗银屑病的临床观察[J].中国麻风皮肤病杂志,2006,22(9)：792.
[97]Kirby B, RichardsHL, McElhon e K, et al. Psychological distress affects the ef ficacy of PUVA in patient s w ith psoriasis. Br J Dermat ol,2000,143 (Suppl 57):15-24
[98]杨雪琴,张高明,张力军.生物反馈治疗银屑病的探讨.中华皮肤科志,1993,26：119-120.
[99]路云环,李桂霞,范慧英.心理治疗对银屑病患者的影响[J].中国麻风皮肤病杂志,2007,23(11)：969.
[100]陈春华,李敏,李涛.心理行为干预对银屑病患者的影响[J].临床护理,2011,9(4)：154.
[101]孔素云,王东.寻常型银屑病89例的心理测查及心理治疗[J].中华现代临床医学杂志,2005,3(16)：1663-1664.
[102]刘巧,吴伟伟,王爱民.系统性心理行为干预对银屑病患者影响的研究[J].中国中西医结合皮肤性病学杂志,2011,10(1)：56-58.
[103]康小平,吴志洪.放松和想象训练与药物联合治疗银屑病疗效分析[J].皮肤性病诊疗学杂志,2011,18(5)：327-328.
[104]王禾,孙丽蕴,邓丙戌等.靛玉红紫草素对角质形成细胞株凋亡的影响[J].中国麻风皮肤病杂志,2003,18(6)：325-327.
[105]刘梅青.不同剂量紫草醇提取物对表皮细胞过度增殖的实验研究[J].临床医药实践杂志2003;12(7)：485.
[106]Arbiser JL, KlauberN, Rohan R, et al. Curcumin is an in vivo in-hibitor of angio2genesis[J]. MolMed,1998,4(6):376.
[107]吴京海,杨思源,金岚等.丹参素对银屑病患者外周血单个核细胞粘附分子表达的影响[J].上海医科大学学报,1998,25(1)：47.
[108]赵喜荣,李冠勇,季军捷等.复方丹参液对银屑病患者血液MDA、SOD及红细胞四项指数的影响[J].临床皮肤科杂志,1995,(4)：25.
[109]王英杰,范慧英,路云环.复方甘草酸苷对银屑病患者T细胞免疫功能的影响[J]中国麻风皮肤病杂志,2007,23(6)：533.
[110]刘晓明,孙秀坤,齐欣,等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素-的影响[J].中华皮肤科杂志,2001,34(4)：282-283.
[111]王学军,陶以成,刘长发.丹槐银屑浓缩丸对小鼠银屑病模型的病理实验研究[J].中国中医急症,2010,19(1)：104-105.
[112]张云璧,瞿幸,牛福玲.常用治疗银屑病的中药对肿瘤坏死因子-α刺激后角质形成细胞生长及分泌白介素-8的影响[J].中国中西医结合皮肤性病学杂志,2006,5(1)：19.
[113]杜锡贤,张春红.张春敏等.清热凉血法治疗进行期寻常型银屑病的临床和实验研究[J].中国麻风皮肤痛杂志.2005,21(11)：896
[114]许能,吴胜利,马绍尧.凉血解毒中药治疗银屑病的实验研究[J].上海中医药大学学报,2004,18(2)：61.
[115]Picardi A,Pasouini P. Toward a biopsychosocial approach to skin diseases [J].Adv Psychosom Med,2007,5 (2):137-144.
[116]M isery L. Sk in, immunity and n ervou s system [J]. B r J Derm ato,l 1997, 137(6):843-850.
[117]谢启文主编.现代神经内分泌学[M].上海：上海医科大学出版社.1999年：69-70
[118]杨道理,罗南萍.银屑病患者NPY、NT、TNF、HA及LN检测的临床意义[J].放射免疫学杂志,1998,11(6)：348-349.